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Introduction: Approximately 10 to 15% of non-small cell lung cancer
patients will be assigned a stage classification according to the 7th
edition of TNM that differs from that assigned by the 6th edition (the
“stage shifters”). This apparent upstaging or downstaging of tumors
may affect patient management, as many clinicians formulate stage-
based management strategies. However, the staging system revision
was not designed to evaluate treatment, and attempts to make parallel
adjustments in treatment plans may not be justified.
Methods: Lung cancer clinicians were surveyed at four lung cancer
symposia. Treatment of the “stage shift” patients was evaluated in
the International Association for the Study of Lung Cancer database
and National Cancer Database.
Results:Overall, 77% of surveyed clinicians indicated they would alter
patient management in response to a change in stage designation.
The analysis of the data in the International Association for the
Study of Lung Cancer database was not directed at supporting
treatment changes. Despite the similar overall prognosis within each
of the “stage shift” subgroups in the National Cancer Database, the
treatment was decidedly heterogeneous.
Conclusions: The perception that a stage change should lead to a
change in management exists. The revision of the lung cancer
staging system does not provide any direct information to indicate
the superiority of one treatment approach over another. Assuming
that overall prognosis of a subgroup is strongly linked to a specific
treatment and that a particular outcome, therefore, warrants a change
in treatment is not justified. Thus, making changes in management
solely in response to upstaging or downstaging in the new stage
classification system is not justified.
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The revised lung cancer stage classification system islikely to have a tremendous impact on the management
of non-small cell lung cancer (NSCLC). The identification
of staging parameters with improved prognostic abilities
has led to the reclassification of 10 subgroups of tumors
from one stage group to another (the “stage shifters”)
(Table 1). However, the influence this apparent upstaging
or downstaging of tumors should have on treatment deci-
sions is unclear.
A link between lung cancer stage and treatment has
been fostered by decades of clinical trials and registry studies
that have reported results by stage. This in turn has led to a
series of stage-specific treatment guidelines (American Col-
lege of Chest Physicians,1,2 National Comprehensive Cancer
Network,3 and American Society of Clinical Oncology4).
This leads to the perception that once the stage grouping of a
tumor is defined, the optimal treatment approach has been
determined as well.
Several lung cancer organizations have recognized
that assignment of a tumor cohort to a different stage group
may have implications for existing treatment algorithms,
including the International Association for Study of Lung
Cancer (IASLC),5 the Health Care Advisory Board (avail-
able at: http://www.advisory.com/), web-based clinician
resources (Oncology STAT),6 and patient advocacy groups
(Lung Cancer Alliance).7 Mainstream media have also
linked the stage classification revision with treatment
change. For example, the cable news channel, MSNBC
stated “New system may give lung cancer patients hope.
Altering policy for treating tumors means more will get
surgery, therapy.”8
We sought to determine the ways in which the
new stage classification system could and should affect
treatment policies. To accomplish this, we evaluated cli-
nician response to changes in stage designation and the
care of the “stage shift” subgroups in two large cancer
databases.
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METHODS
Clinician Survey
Lung cancer clinicians attending four separate confer-
ences in the United States between October and November
2009 were asked to fill out surveys regarding the optimal
treatment strategies for three specified patient scenarios: (1)
Northeast Thoracic Surgery conference; CT, October 24,
2009, (2) New York Advances in Diagnosis and Treatment of
NSCLC; New York City, NY, October 31, 2009, (3) CHEST
Post Graduate Course; San Diego, CA, November 1, 2009,
and (4) Connecticut State Chest Conference, New Haven,
CT, November 18, 2009. The audience for each symposium
was a mixture of surgeons, pulmonologists, medical oncolo-
gists, pathologists, radiologists, physicians in training, and
physician assistants. The overall response rate among the four
conference participants was 32% and ranged from 18 to 55%.
The number of respondents from each conference was North-
east Thoracic Surgery (17), New York Advances (40),
CHEST (29), and Connecticut State Chest (11).
No specific treatment recommendations were made
during the lectures that pertained to the patient scenarios used
in the survey or the effect the stage classification system
should have on treatment.
The survey consisted of three patient scenarios each
associated with a “stage shift” cohort: (1) a tumor with an
additional nodule in the same lobe without nodal metastases,
(2) a tumor 7 cm with a hilar lymph node metastasis, and
(3) a tumor invading vascular structures within the medias-
tinum (T4) without nodal metastases. All tumors were de-
scribed as being amenable to complete surgical resection, and
all patients were able to tolerate any form of therapy. A
complete extent of disease workup was otherwise negative.
The patient scenarios were presented at the beginning of the
lecture bearing their 6th edition (previous) stage designation,
and at the end of the lecture, three different patients repre-
senting the same three clinical scenarios were presented
bearing their 7th edition stage designation. Participants were
asked to choose one of four possible treatment strategies: (A)
chemotherapy radiation, (B) surgery alone, (C) neoadjuvant
chemotherapy, radiation, or both then surgery, or (D) surgery
then adjuvant chemotherapy. Responses were captured anon-
ymously on different sides of the piece of paper used to
administer the survey, so that the treatment chosen for a
patient classified using the 6th edition and the 7th edition
designation could be compared for each respondent. Frequen-
cies of the treatment strategies for the 6th and 7th edition
staging definitions were computed. The proportions of clini-
cians changing their treatment strategy were also calculated.
IASLC Staging Database
The IASLC composite staging database used to revise
the lung cancer staging system contains 81,015 lung cancer
cases diagnosed between 1990 and 2000. The database was
created using 46 sources from 19 countries and is described in
detail elsewhere.5,9,10 The nonprofit organization of Cancer
Research and Biostatistics (CRAB), in Seattle, performed the
analysis for the stage revision and has subsequently been
charged with the oversight of the IASLC staging database for
ongoing study. Research protocols requesting the use of
IASLC database are reviewed by members of the IASLC
staging committee and CRAB.11 In response to our proposal
to study the treatments given to the “stage shift” patients,
IASLC has generously tabulated and posted the treatment
data for patients from the staging database on their website
available at: http://www.iaslc.org/staging_project.asp. How-
ever, treatment was not the focus of the IASLC database
project. Therefore, although tumor characteristics and prog-
nosis were meticulously validated, this did not extend to the
treatment information.
National Cancer Database
The National Cancer Database (NCDB) is a joint pro-
gram of the Commission on Cancer (CoC) and the American
Cancer Society serving as a nationwide oncology outcomes
database for more than 1400 commission-approved cancer pro-
grams in the United States and Puerto Rico. It is estimated that
the database captures 75% of the cancers diagnosed each year in
the United States (detailed description of database available at:
www.facs.org/cancer/ncdb). In 2004, the NCDB began to enter
data according the Collaborative Staging (CS) guidelines infor-
mation (available at: http://cancerstaging.org/cstage). The
NCDB was used in this study because of the detailed treatment
information collected.
In October 2009, the NCDB was queried for cases of
NSCLC. Cases were included if they were the first primary
TABLE 1. The NSCLC “Stage Shifters”
6th Edition Characteristics Former Stage New Stage % IASLC Patients
Upstaged T2 (5 but  7cm) N0 M0 1B 2A 3.8
T2 (7 cm) N0 M0 1B 2B 1.7
T2(7 cm) N1 M0 2B 3A 0.8
Malignant pleural involvement 3B 4 2.5
Downstaged T2(5 cm)N1 2B 2A 4.4
Separate tumor nodules in same lobe, N0 3B 2B 0.6
Separate tumor nodules in same lobe, N1,N2 3B 3A 0.7
Separate tumor nodules in different ipsilateral lobe N0, N1 4 3A 0.4
Separate tumor nodules in different ipsilateral lobe N2,3 4 3B 0.3
T4 (extension) N0,N1 3B 3A 1.6
IASLC, International Association for Study of Lung Cancer; NSCLC, non-small cell lung cancer.
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tumor, diagnosed between 2004 and 2007 with NSCLC,
between 18 and 100 years of age at diagnosis, were not
missing data on CS metastases at diagnosis, CS extension,
tumor size, or tumor, node, and metastasis (T, N, and M), and
the record was obtained from a CoC accredited hospital
(complete data available for 215,251 of the 365,664 patients
entered during this time period). Stage shifter status was then
assessed based on T, N, M tumor size, CS metastases at
diagnosis, and CS extension characteristics. T, N, and M were
classified by pathologic staging information if available,
otherwise clinical was used. Information was obtained re-
garding first course of treatment.
Frequencies and proportions of cases in each of the
stage shifter categories were calculated. Types of treat-
ment received was then determined for cases within each
category of stage shifter. Differences in treatment regi-
mens received within each stage shift subgroup were
calculated by using a 2 test with the Bonferroni correction
for multiple comparisons. A p value 0.01 was considered
significant. All analyses were performed using SPSS ver-
sion 17.0 (Chicago, IL).
Statistics
Data reported to the NCDB are retrospective in nature. No
patient or physician identifiers were collected as part of the
study. Case identification information (facility identification
number and local registry accession number) was collected for
administrative purposes only. The American College of Sur-
geons has executed a Business Associate Agreement that in-
cludes a data-use agreement, with each of its CoC-approved
hospitals. Results reported in this study were in compliance with
the privacy requirements of the Health Insurance Portability and
Accountability Act of 1996 as reported in the Standards for
Privacy of Individually Identifiable Health Information; Final
Rule (45 CFR Parts 160 and 164).
RESULTS
Many Clinicians Are Likely to Change
Treatment in Response to the Staging System
Revisions
To determine the extent to which upstaging or down-
staging of tumors by the new lung cancer staging system
would impact on treatment decisions, lung cancer clinicians
were surveyed as described earlier. Three patient scenarios
were presented twice, first with a previous (6th edition) stage
classification and then with a revised (7th edition) stage
classification (Table 2). An average of 46% of respondents
indicated that they would change management in response to
the stage designation change for each of the three outlined
patient scenarios. Overall, 77% of the 97 clinicians changed
management in at least one of the scenarios.
There Is No Direct Link between the Stage
Revisions and Treatment Approach in the
IASLC Staging Project
Treatment approach was not explicitly included in the
analysis by the IASLC that led to the reclassification of the
stage shift tumors.5 Therefore, there was no direct association
between treatment and the IASLC stage groupings. In fact, in
response to our proposed study of the treatment of stage shift
patients, CRAB (the organization responsible for the colla-
tion, validation, and analysis of the IASLC database) stated
that the database should not be used as evidence to support a
change in treatment strategy for any patient cohort or any
particular stage designation.
A Prognosis-Based Stage Classification Does
Not Define a Consistent Treatment Approach
To evaluate the treatment within prognosis-based stage
subgroups, we queried the NCDB database (in which the
treatment data were validated). Of the 215,251 patients with
NSCLC diagnosed between 2004 and 2007 with complete
data in the NCDB, 22,044 (10.2%) fell into 1 of the 10 “stage
shift” categories outlined in Table 1. The treatment given
within each of these subgroups was markedly heterogeneous,
with no treatment regimen in any of the stage shift subgroups
being received by a majority (50%) of patients (Figure 1)
(2  10,000).
The “Stage Shift” Cohorts in the IASLC
Database May Not Equally Represent All
Patients Defined by These Stage Subgroups
The “stage shift” cohorts in the IASLC database seem to
have important differences compared with the general popula-
tion of patients with NSCLC that may affect the ability to
broadly apply some of the findings. The stage shift subgroups
were larger in the IASLC database, accounting for 17% (n 
4531) of the patients with NSCLC in the IASLC database
compared with only 10% of the NCDB (n  22,044). Much of
this discrepancy lay in the frequency of the larger tumors in the
stage shift subgroups (T2 stage shifters represented 8.2% IASLC
TABLE 2. Lung Cancer Clinician Survey (Listed Value Equals % of Respondents)
Treatment
Additional Nodule—Same
Lobe, N0
>7cm Tumor,
N1()
Mediastinal Invasion,
N0
6th Edition,
T4N0M0
(IIIB)
7th Edition,
T3N0M0
(IIB)
6th Edition,
T2N1M0
(IIB)
7th Edition,
T3N1M0
(IIIA)
6th Edition,
T4N0M0
(IIIB)
7th Edition,
T4N0M0
(IIIA)
Chemotherapy radiation 12 6 4 7 48 46
Surgery alone 17 18 2 1 5 3
Neoadjuvant (chemotherapy, radiation, or both) then surgery 19 7 33 50 27 40
Surgery adjuvant chemotherapy 52 69 61 42 20 11
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database compared with 1.8% of NCDB). In the IASLC data-
base, patients were diagnosed between 1990 and 2000, and most
of the stage shift subgroups were treated by surgery alone, which
is markedly different than the treatment received in cases diag-
nosed between 2004 and 2007 in the NCDB (Tables 3 and 4).
The only exception is the malignant pleural dissemination sub-
group, in which about 40%were treated surgically in the IASLC
database (which is still much higher than the 5% in NCDB).
DISCUSSION
The new stage classification system represents a major
advance in defining a nomenclature of T, N, and M charac-
teristics of lung cancer. Furthermore, the reorganization of
staging parameters into a revised classification system has
resulted in a significantly improved stratification of survival
among the staging subgroups. However, it is unclear how
these changes would impact the large number of “stage shift”
tumors diagnosed each year (an estimated 30,000 in the
United States alone).12 Our current analysis indicates that a
substantial number of the patients with “stage shift” tumors
may be treated differently than they would have been under
the previous stage classification.
Detailed analysis of treatment data was beyond the
scope of the IASLC staging project, and there is no direct
connection between the changes in the stage classification
system and the treatment approach. This alone precludes
using a change in stage designation to justify a change in
treatment strategy. Indeed the IASLC has repeatedly empha-
sized that any changes secondary to reclassification in the 7th
edition must be evaluated by appropriate clinical trials. The
same sentiment is expressed by the editors of the AJCC
staging manual “Comparison of survival curves by treatment
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FIGURE 1. Treatment of the stage shifters in the National
Cancer Database (NCDB). Each of the stage shift subgroups
are represented on the “x” axis. The relative frequency of
the various treatment approaches is represented along the
“y” axis for each subgroup as defined in the legend. Ch,
chemotherapy; RT, radiotherapy; ChRT, chemoradiotherapy;
Ch-S, chemotherapy then surgery; ChRT-S, chemoradiother-
apy then surgery; S, surgery alone; S-Ch, surgery then che-
motherapy; S-ChRT, surgery then chemoradiotherapy; S-RT,
surgery then radiotherapy; NoTmt, no treatment; Pl effus,
pleural effusion; satell, satellite nodule; Ipsi Nod, ipsilateral
nodule in different lobe; inv, invasion.
TABLE 3. Treatment of Stage Shifters in the IASLC Staging Database (% of Total Within Stage Shift Category)
6th Edition Characteristics N
Chemo
Only
XRT
Only
Chemo
XRT
Surgery
Only
Surgery
Chemo  XRT
BSC or
Unknown
T2 (5 but  7 cm) N0 M0 1016 0 8 (1) 2 (1) 927 (91) 78 (8) 1 (1)
T2 (7 cm) N0 M0 457 0 2 (1) 0 422 (92) 33 (7) 0
T2(7 cm) N1 M0 205 0 0 1 (1) 175 (85) 29 (14) 0
Malignant pleural involvement 683 268 (39) 10 (1) 11 (2) 257 (38) 28 (4) 109 (16)
T2(5 cm)N1 1184 1 (1) 10 (1) 3 (1) 1052 (89) 118 (10) 0
Separate tumor nodules in same lobe, N0 174 0 0 0 164 (94) 10 (6) 0
Separate tumor nodules in same lobe, N1, N2 197 0 0 0 181 (92) 14 (7) 2 (1)
Separate tumor nodules in different ipsilateral lobe N0, N1 97 0 0 1 (1) 80 (82) 14 (14) 2 (2)
Separate tumor nodules in different ipsilateral lobe N2,3 86 2 (2) 1 (1) 0 69 (73) 8 (9) 6 (7)
T4 (extension) N0,N1 432 1 (1) 19 (4) 28 (6) 296 (68) 81 (19) 7 (2)
Total 4531 272 (6) 50 (1) 46 (1) 3623 (80) 413 (9) 127 (3)
Chemo, chemotherapy; XRT, radiotherapy; BSC, best supportive care; IASLC, International Association for Study of Lung Cancer.
TABLE 4. Comparison of IASLC and NCDB Treatment of “Stage Shifters”
Up- or Downstaged Patients n
Surgery
Only (%)
Radiotherapy
Only (%)
Chemotherapy
Only (%) Multimodality (%)
BSC or
Unknown (%)
IASLC database 4531 80 1 6 10 3
NCDB database 22,044 19 10 14 40 17
IASLC, International Association for Study of Lung Cancer; BSC, best supportive care; NCDB, National Cancer Database.
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is most appropriately accomplished within the confines of
randomized clinical trials.”13 Analysis of the NCDB database
demonstrates the complexity of choosing a treatment for a
patient. The high degree of variability illustrates the complex
process of aligning patients with treatment, even in the era of
stage specific guidelines. Therefore, the assumption that patients
within a prognosis-based stage subgroup receive similar treat-
ment ignores significant differences that affect treatment choices
(e.g., comorbidities, prior treatment, tumor resectability, perfor-
mance status, patient choice, and clinician preference).
Clinicians may be tempted to look at the prognosis as
defined by the IASLC database of a stage shift subgroup as a
justification to change the treatment approach. However,
outcomes are influenced by the treatment given (one would
hope), and this has been heterogeneous. By design, the
IASLC staging database contained a large number of patho-
logically staged patients (63%), which would tend to favor
surgical treatment.5 The IASLC database included data from
a number of treatment-specific clinical trials and registries
from Europe, Asia, Australia, and North America, whereas
the NCDB represents a large hospital-based sample, which is
restricted to the United States (75% of all patients in the
United States). These geographic differences no doubt in-
clude variations in epidemiology, cell type, and treatment.
Furthermore, the IASLC stage classification project basis
for distinguishing distinct T, N, and M descriptors and stage
groupings was not the prognosis per se but differences in
prognosis, which had to be consistent across continents,
types of source databases, and other factors. In addition,
the IASLC patients were treated 10 to 20 years ago, and
prognosis has changed during this time.14–16 Therefore,
although the stage classification system provides an esti-
mate of prognosis, these values should not be taken liter-
ally, particularly in cases of treatment decisions, where the
difference in outcomes between superior and inferior ap-
proaches may be subtle.
Finally, the concept of a stage-specific treatment algo-
rithm is in many ways an oversimplification. As described
previously, many factors besides a prognosis-based stage desig-
nation must be considered. In addition, looking to an overall
stage group assignment to determine treatment ignores the fact
that specific subgroups within a stage group are often candidates
for a particular treatment regimen (that other members of the
stage group are not). For example, the American College of
Chest Physicians lung cancer management guidelines devote a
separate chapter (Special Treatment Issues) to patients for whom
special treatment strategies apply (which are often different than
that for the overall stage group they fall into).17 It is interesting
to note that many of these tumor subgroups receiving special
consideration (T4 extension, multiple nodules in the same lobe)
are in fact “stage shift” cohorts.
In conclusion, there is a potential for lung cancer
clinicians to wrongly assume that changes in stage designa-
tion within the new stage classification system justify specific
changes in treatment approach. The new staging system is
invaluable in providing a nomenclature to describe tumor
characteristics and provides a validated basis for distinguish-
ing pertinent features and subgroups of NSCLC tumors.
However, the 7th edition of the stage classification system
provides no direct analysis with respect to treatment. Even
the prognosis of subgroups as reported in the staging publi-
cations does not lend itself to specific recommendations about
the right treatment approach because of heterogeneity, con-
founding factors, and lack of linkage to particular treatments
given. The results of clinical trials involving defined treat-
ments in defined patients must remain the basis for selecting
the optimal treatment approach.
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